Tacrolimus ointment: utilization patterns in children under age 2 years
- PMID: 15347484
Tacrolimus ointment: utilization patterns in children under age 2 years
Abstract
Atopic dermatitis (AD) is a common eczematous skin condition; as many as 10-17 percent of all children are affected, and 35-60 percent of affected patients manifest symptoms manifest during the first year of life. Treatment principles for AD in young children involve conservative measures such as avoidance of hot water and environmental irritants, combined with liberal use of emollients after bathing. Low potency topical corticosteroids (TCS) are the current standard of therapy for AD in young children, reserving mid- and high-potency TCS for severe disease. However, complications of long-term use of TCS include skin atrophy, stria formation, telangiectasia, hypopigmentation, secondary infections, steroid acne, allergic contact dermatitis, and miliaria. The pediatric population is also at increased risk for systemic absorption because of their high ratio of skin surface to body mass. Systemic absorption may result in hypothalamic-pituitary-adrenal axis suppression and ultimately growth retardation. Although most topical and systemic corticosteroids are not approved by the Food and Drug Administration for use in children less than 2 years of age, conservative treatment often fails in this age group and frequently patients are treated with TCS, antibiotics, and antihistamines.
Similar articles
-
Tacrolimus ointment: new preparation. Too many unknowns.Prescrire Int. 2004 Jun;13(71):86-9. Prescrire Int. 2004. PMID: 15233141
-
Efficacy and safety of tacrolimus ointment in pediatric Patients with moderate to severe atopic dermatitis.J Med Assoc Thai. 2006 Nov;89(11):1915-22. J Med Assoc Thai. 2006. PMID: 17205874 Clinical Trial.
-
A single-center open-label long-term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis.J Dtsch Dermatol Ges. 2008 Jul;6(7):548-53. doi: 10.1111/j.1610-0387.2008.06641.x. Epub 2008 Jan 30. J Dtsch Dermatol Ges. 2008. PMID: 18248495 Clinical Trial. English, German.
-
The role of topical calcineurin inhibitors in atopic dermatitis.Br J Dermatol. 2004 Dec;151 Suppl 70 Dec 2004:3-27. doi: 10.1111/j.1365-2133.2004.06269.x. Br J Dermatol. 2004. PMID: 15548171 Review.
-
Topical tacrolimus: a new therapy for atopic dermatitis.Am Fam Physician. 2002 Nov 15;66(10):1899-902. Am Fam Physician. 2002. PMID: 12469964 Review.
Cited by
-
Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions.Drugs. 2005;65(6):827-58. doi: 10.2165/00003495-200565060-00011. Drugs. 2005. PMID: 15819596 Review.
-
Nonsteroidal Topical Immunomodulators in Allergology and Dermatology.Biomed Res Int. 2016;2016:5185303. doi: 10.1155/2016/5185303. Epub 2016 Apr 6. Biomed Res Int. 2016. PMID: 27144167 Free PMC article. Review.
-
FK506 (tacrolimus) causes pain sensation through the activation of transient receptor potential ankyrin 1 (TRPA1) channels.J Physiol Sci. 2019 Mar;69(2):305-316. doi: 10.1007/s12576-018-0647-z. Epub 2018 Nov 26. J Physiol Sci. 2019. PMID: 30478741 Free PMC article.
-
Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues.Paediatr Drugs. 2007;9(5):289-99. doi: 10.2165/00148581-200709050-00002. Paediatr Drugs. 2007. PMID: 17927301 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources